Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial(Emory University), Brendan M. Weiss(University of Pennsylvania), Saad Z. Usmani(Carolinas Healthcare System), Seema Singhal(Northwestern University), Ajai Chari(Icahn School of Medicine at Mount Sinai), Nizar J. Bahlis(University of Calgary), Andrew R. Belch, Amrita Krishnan(City of Hope), Robert Vescio(Cedars-Sinai Medical Center), María‐Victoria Mateos(Instituto de Investigación Biomédica de Salamanca), Amitabha Mazumder(NYU Langone Health), Robert Z. Orlowski(The University of Texas MD Anderson Cancer Center), Heather J. Sutherland(University of British Columbia), Joan Bladé(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Emma C. Scott(Oregon Health & Science University), Albert Oriol(Institut Català d'Oncologia), Jesús G. Berdeja(Sarah Cannon), Mecide Gharibo(Rutgers Cancer Institute), Don A. Stevens(Norton Healthcare), Richard LeBlanc(Hôpital Maisonneuve-Rosemont), Michaël Sébag(Royal Victoria Hospital), Natalie S. Callander(University of Wisconsin–Madison), Andrzej Jakubowiak(University of Chicago), Darrell White(Dalhousie University), Javier de la Rubia(Valencia Catholic University Saint Vincent Martyr), Paul G. Richardson(Dana-Farber Cancer Institute), Steen Lisby(Genmab (Denmark)), Huaibao Feng(Janssen (United States)), Clarissa Uhlar(Janssen (United States)), Imran Khan(Janssen (United States)), Tahamtan Ahmadi(Janssen (United States)), Peter M. Voorhees(University of North Carolina at Chapel Hill)
Cited by 849
Abstract
Related Papers
No related papers found
Powered by citation graph analysis